AI-based Antibody Development Platform
Technology
AI-based antibody development platform Overview
KY-AITM is our proprietary artificial intelligence platform for antibody drug development. Built upon the revolutionary alphafold2 algorithm, our specialized software can accurately predict antigen-antibody complex structures and binding affinities with lighting speed, therefore, is able to perform large-scale in silico screening of antibody sequence library generated from NGS to select promising antibody drug candidates against therapeutic targets such as proteins and tumor antigens.
Our software is also able to perform affinity maturation by simultaneously substituting multiple amino acid residues to generate novel antibodies with stronger and more specific binding to a therapeutic target. KY-AITM greatly speeds up antibody drug development with significantly reduced experimental cost and time.
Technology
Genetically engineered cell lines
Genetically engineered cell lines revolutionize research, enabling precise studies on diseases, therapies, and biological processes for innovative medical advancements.
In vitro and in vivo pharmacology
In vitro pharmacology explores drug effects in controlled lab settings, while in vivo studies investigate drug responses within living organisms.
Bispecific and tri-specific antibody discovery platform
Revolutionize immunotherapy with our cutting-edge Bispecific and Tri-specific Antibody Discovery Platform, enhancing precision and efficacy in targeted cancer treatments
MPSA-AB5000 panel
Genetically engineered cell lines revolutionize research, enabling precise studies on diseases, therapies, and biological processes for innovative medical advancements.
AI-based antibody development platform
Revolutionize immunotherapy with our cutting-edge Bispecific and Tri-specific Antibody Discovery Platform, enhancing precision and efficacy in targeted cancer treatments
